Certifications
Transplant Hepatology
Gastroenterology
Education
MD, Columbia Univ. Col. of Phy. & Surg.
BA, Barnard College
BiologyMD, Columbia University College of Physicians and Surgeons
Beth Israel Hospital
MedicineColumbia Presbyterian Medical Center
MedicineColumbia Presbyterian Medical Center
GastroenterologyMount Sinai Medical Center
HepatologyInternship, Internal Medicine
Beth Israel Deaconess Medical Center- Harvard Medical SchoolResidency, Internal Medicine
Columbia-Presbyterian Medical CenterFellowship, Gastroenterology
Columbia University College of Physicians & SurgeonsFellowship, Hepatology
Mount Sinai Hospital
Biography
- Dr. Kim-Schluger is the Associate Director of The Recanati/Miller Transplantation Institute.
Dr. Kim -Schluger's expertise is the management of liver transplant recipients, as well as on the natural course and treatment of hepatitis C. Among her research efforts have been studies that named to identify different treatment options for patients with hepatitis C virus infection; to better understand the course of hepatitis C after liver transplantation and to determine the best immunosuppressive drug regimens for liver transplant recipients. Dr. Kim-Schluger also has a special interest in the controversial issues and ethical dilemmas of organ allocation.
In the News
Dr. Kim-Schluger discusses hepatitis C in The Daily News feature The Daily Check Up.
View the PDF
Visit RMTI website: www.mountsinaiRMTI.org
Awards
1988 -
Alpha Omega Alpha
1988 -
The Harry S. Altman Prize in Pediatrics
1983 -
Phi Beta Kappa
1980 -
The Governor's Scholarship for Academic Excellence
1979 -
The Governor's Scholarship for Academic Excellence
Publications
Kim-schluger H, Rotterdam H, Lebwohl O. Gastrointestinal hemorrhage from a Brunner's gland hamartoma. Am J Gastroenterology 1995; 21(2): 584-588.
Gurkan A, Emre S, Foshbein TM, Brady L, Millis M, Birnbaum A, Kim-schluger H, Sheiner PA. Unsuspected bile duct paucity in donors for living-related liver transplantation: two case reports. Transplantation 1999; 67: 416-418.
Guy SR, Magliocca JF, McDonough P, Emre S, Kim-schluger H, Sheiner PA, Fishbein TM, Schwartz ME, Miller CM. . Transmission of factor VII deficiency through liver transplantation. Transplant Int 1999; 12: 278-280.
Emre S, Schwartz ME, Shneider B, Hojsak J, Kim-schluger H, Fishbein TM, Guy SR, Sheiner PA, LeLeiko NS, Birnbaum A, Suchy FJ, Miller CM. Living related liver transplantation for acute liver failure in children. Transpl Surg 1999;: 161-165.
Martins PN, Kim-Schluger L, Rodriguez-Davalos M, Martins AB, Krachkova N, Facciuto M, Sheiner P. Massive pulmonary and intracardiac embolism during liver transplantation. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2010 Jun; 8(2).
Kim-schluger H, Emre S, Guy SR, Sheiner PA, Fishbein TM, Schwartz ME, Miller CM. Safe transplantation of blood type A2 livers to blood type O recipients. Transplantation 1999; 67: 1071-1073.
Sheiner PA, Magliocca JF, Bodian CA, Kim-schluger H, Altaca G, Guarrera JV, Emre S, Fishbein T, Guy SR, Schwartz ME, Miller CM. Long-term medical complications in patients surviving [greater than or equal to] 5 years after liver transplant. Transplantation 2000; 69: 781-789.
Sheiner PA, Magliocca JF, Bodian CA, Kim-schluger H, Altaca G, Guarrera JV, Emre S, Fishbein TM, Guy SR, Schwartz ME, Miller CM. . Long-term medical complications in patients surviving 5 years after liver transplant. Transplantation 2000; 69: 781-789.
Emre S, Genyk Y, Kim-schluger H, Fishbein T, Guy SR, Sheiner P, Schwartz ME, Miller CM. Treatment of tacrolimus related adverse effects by conversion to cyclosporine in \tliver transplant recipients. Transplant International 2000;.
Brodsky N, Jaffe DL, Kim-Schluger L, Bodenheimer HC, Bach N. Decompensated Liver Disease associated with Hereditary Hemorrhagic Telangiectasia.;.
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Kim-Schluger did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Bldg 1425 Madison Avenue
3rd Floor
New York, NY 10029
Fax: 212-348-2474
5 East 98th Street
12th Floor
New York, NY 10029
